NEW
YORK, May 15, 2023 /PRNewswire/ -- Thorne
HealthTech, Inc. ("Thorne") (NASDAQ: THRN), a leader in
delivering innovative solutions for a personalized approach to
health and wellness, announced today that it is entering into a
research and development partnership agreement with Arome Science,
a leader in metabolomics, to develop a next-generation metabolomics
test.
Arome Science and Thorne will collaborate to develop a
commercial metabolomics wellness test. The test will be used to
support research studies using at-home blood collection via
Thorne's OneDraw® medical device, which was recently selected as
Best Overall Medical Device Product in the 2023 MedTech
Breakthrough Awards. The metabolomics test will be further
developed and validated for an eventual offering in the consumer
space.
"Metabolomics measurements are the next wave of important
datasets that will give consumers greater control and a better
understanding of their health," said Dr. Nathan Price, Chief Scientific Officer of Thorne
HealthTech. "There are thousands of metabolites in the body that
can be measured, which can reveal key insights into helping
individuals live healthier longer. Thorne's belief in personalized
scientific wellness and the power of metabolomics is further fueled
by our partnership with Arome Science and partnering together to
develop a test that can provide an incredibly personalized view of
one's health from the comfort of their own home."
Developing this metabolomics test continues to advance Thorne's
industry-leading health ecosystem, bringing together advanced
testing, AI-driven insights, and the ability to deliver
personalized solutions through more than 300 natural products
manufactured at the highest quality.
"From our near pain-free OneDraw experience to our proprietary
microbiome wipe, our commitment to providing a best-in-class
integrated experience to our customers is what we are working on
constantly and take great pride in," said Paul Jacobson, CEO of Thorne HealthTech. "As we
develop the metabolomics test and work with Arome, this will enable
us to further deliver and expand on our promise of deep
personalization to support and enhance the health and wellness of
our customers."
"Metabolomics testing is arguably one of the most informative
ways to understand the real-time status of an individual's health,"
said Alexey Melnik, CEO of Arome
Science. "Our research and development partnership with Thorne
makes way for the development of a powerful metabolomics test that
will be used for research studies and ultimately by consumers."
About Thorne HealthTech:
Thorne HealthTech is a leader
in developing innovative solutions for delivering personalized
approaches to health and wellness. As a science-driven wellness
company that empowers individuals with the support, education, and
solutions they need to achieve healthy aging – living healthier
longer – Thorne utilizes testing and data to create improved
product efficacy and to deliver personalized solutions to
consumers, health professionals, and corporations. Predicated on
the power of the individual, Thorne leverages artificial
intelligence models to provide insights and personalized data,
products, and services that help individuals take a proactive and
actionable approach to improve and maintain their health over a
lifetime. Thorne is the only supplement manufacturer that
collaborates with Mayo Clinic on health and wellness research and
content, and is trusted by more than five million customers,
47,000+ health-care professionals, thousands of professional
athletes, more than 100 professional sports teams, and multiple
U.S. National Teams. For more information, visit
Thorne.com.
About Arome Science:
Arome Science Inc is a
biotechnology company that providing metabolomics data acquisition,
analysis and interpretation services for clinical and
pharmaceutical research. A stream of recent discoveries revealed
associations between human microbiome imbalance and chronic
diseases. New approaches to human health and therapeutics that will
in all likelihood revolutionize current medicine and biotechnology
are now being developed. Metabolomics has become a cornerstone
technology as it reveals molecular mechanisms underpinning
biological processes, such as interactions between host and
microbiome. Arome Science is at the forefront of democratizing mass
spectrometry analysis for metabolomics, to make it accessible to
those who need it. Arome uses advanced data acquisition methods
paired with algorithms and machine learning strategies to analyze
mass spectrometry-based metabolomics data and provide valuable
interpretations for its clients. Arome Science Inc. supports
translational and clinical development programs, focused on, but
not limited to, those that leverage the therapeutic and diagnostic
potential of the host microbiome.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/thorne-healthtech-enters-into-research-and-development-partnership-with-arome-science-to-develop-next-generation-metabolomics-test-301823922.html
SOURCE Thorne HealthTech, Inc.